Allarity Therapeutics, Inc

Allarity Therapeutics, Inc. is a clinical-stage precision medicine company based in Boston, MA, focused on advancing stenoparib, an orally available small molecule inhibitor aimed at treating advanced recurrent ovarian cancer. Utilizing its proprietary Drug Response Predictor (DRP) technology, the company seeks to enhance patient outcomes through personalized cancer care by identifying patients most likely to benefit from their innovative therapies.

Stenoparib uniquely targets DNA damage repair enzymes and cell division growth enzymes, distinguishing it from other PARP inhibitors with its dual-action mechanism. With promising results from early clinical trials, Allarity aims to address critical unmet needs in cancer treatment, particularly for patients who have developed resistance to existing therapies.

Generated from the website